11.11.2009 • News

Altana Still Burdened by Economic Crisis

Altana posted considerably lower first-half sales and earnings than in the comparative period of the previous year on account of the worldwide economic crisis. In comparison with the preceding first three months of 2009 the sales performance in the period April to June showed a positive trend; it was not possible, however, to offset the very weak first quarter of the business year. In total, Altana recorded significant losses in sales and earnings in the first six months of 2009. Sales decreased by 25 % to €541.0 million, down from €716.8 million in the same period a year ago. Ebitda decreased by 52 %, from €141.4 million in the previous year to €68.0 million. The Ebitda margin was down to 12.6 % and is therefore lower than the value of 19.7 % of the previous year. Earnings before taxes amounted to €24.5 million, following €103.6 million in the prior year.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.